Related Experiment Video
Updated: Jul 17, 2025
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
Prognostic Implications of RAB35 and its Relationship With Immune Microenvironment in Pan-cancer
Context:
Ras-associated binding 35 (RAB35) is an oncogenic, guanosine triphosphate (GTP)ase that plays a role in cancer invasion, metastasis, and immune evasion. However, systematic and comprehensive research to identify the importance of RAB35 in various cancer types is still absent.
Objective:
The study intended to explore the potential value of RAB35 as a molecular biomarker.
Design:
The research team performed a genetic evaluation of RAB35.
Setting:
The study took place at the Second Affiliated Hospital of Wenzhou Medical University in Wenzhou, China.
Outcome Measures:
The research team assessed the expression of RAB35 in various tumor tissues and performed correlation analyses between RAB35 expression and prognosis, molecular subtypes, immunological subtypes, immune-associated cell infiltration, the tumor immune microenvironment, and drug sensitivity in pan-cancer.
Results:
RAB35 exhibited significant differential expression for 21 cancer types. It demonstrated high sensitivity and specificity in diagnosing eight cancer types, showed distinct expression patterns in various molecular subtypes for six cancer types, and found different immune subtypes for eight cancer types. The abnormal expression of RAB35 was significantly related to overall survival (OS) for nine cancer types, progress free interval (PFI) for five cancer types, and disease-specific survival (DSS) for five cancer types. Its abnormal expression was closely associated with the immune microenvironment and multiple immune cells. Furthermore, it was related to the drug sensitivity for various drugs and might be associated with chemotherapy resistance.
Conclusions:
RAB35 showed significant differential expression in various cancers and was significantly related to the prognosis of cancer patients, the immune microenvironment, multiple immune cells, drug sensitivity to various drugs, and chemotherapy resistance. It may serve as a potential biomarker and therapeutic target for cancer treatment.
Insights
Ras-associated binding 35 (RAB35) is differentially expressed across 21 cancer types, showing potential as a diagnostic biomarker. Its expression impacts patient prognosis, immune microenvironment, and drug sensitivity, suggesting it as a therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genomics
Background:
- Ras-associated binding 35 (RAB35) is an oncogenic GTPase implicated in cancer progression, including invasion, metastasis, and immune evasion.
- Despite its known roles, comprehensive research on RAB35's significance across diverse cancer types is lacking.
Purpose of the Study:
- To investigate the potential of RAB35 as a molecular biomarker in various cancers.
- To evaluate the association of RAB35 expression with clinical outcomes, tumor characteristics, and treatment response.
Main Methods:
- Genetic evaluation of RAB35 expression in tumor tissues.
- Correlation analyses of RAB35 expression with prognosis, molecular and immunological subtypes, immune cell infiltration, tumor immune microenvironment, and drug sensitivity across pan-cancer datasets.
Main Results:
- RAB35 showed significant differential expression in 21 cancer types, with high diagnostic sensitivity and specificity in eight.
- Abnormal RAB35 expression correlated significantly with overall survival, progression-free interval, and disease-specific survival in multiple cancer types.
- RAB35 expression was linked to the tumor immune microenvironment, immune cell infiltration, drug sensitivity, and potential chemotherapy resistance.
Conclusions:
- RAB35 is differentially expressed in various cancers and serves as a potential prognostic biomarker.
- RAB35's association with the immune microenvironment and drug sensitivity highlights its potential as a therapeutic target for cancer treatment.
More Related Videos
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
09:32Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
Related Concept Videos
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:23Abnormal Proliferation
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...